Search for Tradename: COREG CR

Summary for Tradename: COREG CR

Patents:	4
Applicants:	1
NDAs:	1
2009 Sales:	$253,377,000
Therapeutic Class:	Cardiovascular Agents

Latest news for COREG

Flamel Technologies Announces Three New Partnership Agreements; Second Quarter 2010 Results

28 July 2010, 4:16 pm

Ask Dr. Gott: Post-op struggle a surprise

10 July 2010, 4:50 am

Courtesy of Yahoo News

Glossary

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Exclusivity Expiration
Sb Pharmco	COREG CR	carvedilol phosphate	022012	Oct 20, 2006	RX	No	Apr 20, 2010
Sb Pharmco	COREG CR	carvedilol phosphate	022012	Oct 20, 2006	RX	No	Aug 28, 2009
Sb Pharmco	COREG CR	carvedilol phosphate	022012	Oct 20, 2006	RX	No	Feb 28, 2010

Export available with Ultimate Plan subscription:

This preview shows a limited data set. Complete access is available with a Subscription

Paragraph IV activity for: COREG CR

Drugname	Dosage	Strength	RLD	Submissiondate
carvedilol phosphate	Extended-release Capsules	10 mg and 20 mg	Coreg CR	3/18/2008
carvedilol phosphate	Extended-release Capsules	40 mg	Coreg CR	12/21/2007
carvedilol phosphate	Extended-release Capsules	80 mg	Coreg CR	11/19/2007

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:
2000 2001 2002 2003 2004
2005 2006 2007 2008 2009

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Follow DrugPatentWatch on Twitter

Bookmark or Share This Page ...